BioNTech SE SEC filings BNTX

BioNTech SE has 589 filings in SEC EDGAR's recent list, going back to Jun 19, 2019. Its latest annual report, Form 20-F, was filed on Mar 10, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.

Form Description Filed Period
20-F/A Amended annual report (foreign issuer) Jul 30, 2026 Dec 31, 2025
20-F/A Amended annual report (foreign issuer) Apr 1, 2026 Dec 31, 2025
20-F Annual report (foreign issuer) Mar 10, 2026 Dec 31, 2025
20-F Annual report (foreign issuer) Mar 10, 2025 Dec 31, 2024
20-F Annual report (foreign issuer) Mar 20, 2024 Dec 31, 2023
20-F Annual report (foreign issuer) Mar 27, 2023 Dec 31, 2022
20-F/A Amended annual report (foreign issuer) Oct 26, 2022 Dec 31, 2021
20-F Annual report (foreign issuer) Mar 30, 2022 Dec 31, 2021
20-F Annual report (foreign issuer) Mar 30, 2021 Dec 31, 2020
20-F Annual report (foreign issuer) Mar 31, 2020 Dec 31, 2019

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BNTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Germany
Headquarters
Mainz, Germany
SEC filer status
Large accelerated filer
SEC CIK
1776985

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.